Risk for VTE in relatives according to the genotype and clinical presentation of the proband
| Proband characteristics . | Risk for VTE in relatives . | ||||||
|---|---|---|---|---|---|---|---|
| n (M/F) . | Age, y . | Patient-years . | VTE, n (%) . | VTE Incidence (95% CI)* . | Hazard ratio (95% CI) . | adjHazard ratio (95% CI)† . | |
| Homozygous and VTE – | 226 (102/124) | 36 (23-56) | 8670 | 3 (1) | 0.35 (0.06-0.86) | 1‡ | 1‡ |
| Homozygous and VTE + | 305 (125/180) | 37 (25-53) | 11884 | 6 (2) | 0.50 (0.18-1.00) | 1.53 (0.38-6.12) | 1.32 (0.32-5.35) |
| Heterozygous and VTE – | 122 (48/74) | 41 (30-58) | 5243 | 4 (3) | 0.76 (0.19-1.70) | 2.07 (0.46-9.26) | 2.31 (0.51-10.55) |
| Heterozygous and VTE + | 233 (105/128) | 39 (27-55) | 9169 | 14 (6) | 1.53 (0.82-2.46) | 4.46 (1.28-15.55) | 4.14 (1.17-14.71) |
| Proband characteristics . | Risk for VTE in relatives . | ||||||
|---|---|---|---|---|---|---|---|
| n (M/F) . | Age, y . | Patient-years . | VTE, n (%) . | VTE Incidence (95% CI)* . | Hazard ratio (95% CI) . | adjHazard ratio (95% CI)† . | |
| Homozygous and VTE – | 226 (102/124) | 36 (23-56) | 8670 | 3 (1) | 0.35 (0.06-0.86) | 1‡ | 1‡ |
| Homozygous and VTE + | 305 (125/180) | 37 (25-53) | 11884 | 6 (2) | 0.50 (0.18-1.00) | 1.53 (0.38-6.12) | 1.32 (0.32-5.35) |
| Heterozygous and VTE – | 122 (48/74) | 41 (30-58) | 5243 | 4 (3) | 0.76 (0.19-1.70) | 2.07 (0.46-9.26) | 2.31 (0.51-10.55) |
| Heterozygous and VTE + | 233 (105/128) | 39 (27-55) | 9169 | 14 (6) | 1.53 (0.82-2.46) | 4.46 (1.28-15.55) | 4.14 (1.17-14.71) |